• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    5 Value Stocks To Watch In The Healthcare Sector

    2/5/24 9:44:25 AM ET
    $KPRX
    $PROC
    $QNRX
    $SLDB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KPRX alert in real time by email

    What Defines a Value Stock?

    A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.

    Below is a list of notable value stocks in the healthcare sector:

    1. Kiora Pharmaceuticals (NASDAQ:KPRX) - P/E: 1.01
    2. Voyager Therapeutics (NASDAQ:VYGR) - P/E: 6.42
    3. Quoin Pharmaceuticals (NASDAQ:QNRX) - P/E: 2.39
    4. Procaps Gr (NASDAQ:PROC) - P/E: 7.27
    5. Solid Biosciences (NASDAQ:SLDB) - P/E: 0.1

    Kiora Pharmaceuticals's earnings per share for Q3 sits at $-0.89, whereas in Q2, they were at -0.79. Most recently, Voyager Therapeutics reported earnings per share at $-0.59, whereas in Q2 earnings per share sat at $-0.51. Quoin Pharmaceuticals has reported Q3 earnings per share at $-1.95, which has increased by 8.45% compared to Q2, which was -2.13. Most recently, Procaps Gr reported earnings per share at $0.08, whereas in Q2 earnings per share sat at $0.27. This quarter, Solid Biosciences experienced an increase in earnings per share, which was $-1.25 in Q2 and is now $-1.05.

    The Significance: A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.

    Get the next $KPRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KPRX
    $PROC
    $QNRX
    $SLDB

    CompanyDatePrice TargetRatingAnalyst
    Solid Biosciences Inc.
    $SLDB
    12/4/2025$16.00Buy
    Needham
    Solid Biosciences Inc.
    $SLDB
    6/26/2025$14.00Buy
    Citigroup
    Voyager Therapeutics Inc.
    $VYGR
    1/10/2025Overweight
    Cantor Fitzgerald
    Solid Biosciences Inc.
    $SLDB
    1/8/2025$16.00Buy
    Truist
    Solid Biosciences Inc.
    $SLDB
    12/13/2024$16.00Outperform
    Wedbush
    Solid Biosciences Inc.
    $SLDB
    12/10/2024$15.00Mkt Outperform
    JMP Securities
    Voyager Therapeutics Inc.
    $VYGR
    12/2/2024$12.00Buy
    Citigroup
    Voyager Therapeutics Inc.
    $VYGR
    11/29/2024$7.00 → $11.00Outperform
    Wedbush
    More analyst ratings

    $KPRX
    $PROC
    $QNRX
    $SLDB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham initiated coverage on Solid Biosciences with a new price target

    Needham initiated coverage of Solid Biosciences with a rating of Buy and set a new price target of $16.00

    12/4/25 8:48:04 AM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Citigroup initiated coverage on Solid Biosciences with a new price target

    Citigroup initiated coverage of Solid Biosciences with a rating of Buy and set a new price target of $14.00

    6/26/25 8:11:57 AM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cantor Fitzgerald initiated coverage on Voyager Therapeutics

    Cantor Fitzgerald initiated coverage of Voyager Therapeutics with a rating of Overweight

    1/10/25 9:15:32 AM ET
    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KPRX
    $PROC
    $QNRX
    $SLDB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Solid Biosciences Announces Oversubscribed $240 Million Private Placement

    CHARLESTOWN, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors for an approximately $240 million private placement, before deducting placement agent fees and offering expenses, which is expected to close on or about March 9, 2026, subject to the satisfaction of customary closing conditions. The private placement is being conducted in accordance with applicable Nasdaq rules and was priced to satisfy the "Minimum Price" requirement

    3/6/26 8:31:00 AM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Solid Biosciences to Present at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

    CHARLESTOWN, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced presentations on SGT-003, its next-generation investigational gene therapy for Duchenne muscular dystrophy, and SGT-212, its dual-route investigational gene therapy for Friedreich's ataxia (FA), at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, taking place in Orlando, Florida, March 8-11, 2026. Oral PresentationTitle: Update on the INSPIRE DUCHENNE Phase 1/2 Study of the Next-Generation Microdystrophin Gene Therapy Candidate SGT-003 for Duchenne M

    3/6/26 8:30:00 AM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CHARLESTOWN, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 17,600 restricted stock units ("RSUs") to one newly hired employee. The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the applicable employee's continued service with the Company through each applicable vesting date. This grant was made pursuant to the Company's 2024 Inducement Stock Incentive Plan and was made as an inducement

    3/2/26 4:05:00 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KPRX
    $PROC
    $QNRX
    $SLDB
    SEC Filings

    View All

    Solid Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities

    8-K - Solid Biosciences Inc. (0001707502) (Filer)

    3/6/26 4:36:43 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Voyager Therapeutics Inc.

    144 - Voyager Therapeutics, Inc. (0001640266) (Subject)

    2/24/26 5:10:03 PM ET
    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Voyager Therapeutics Inc.

    144 - Voyager Therapeutics, Inc. (0001640266) (Subject)

    2/24/26 5:09:40 PM ET
    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KPRX
    $PROC
    $QNRX
    $SLDB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Langer Dennis bought $128,640 worth of ADSs (15,152 units at $8.49), increasing direct ownership by 1,515,200% to 15,153 units (SEC Form 4)

    4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)

    10/15/25 5:15:20 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    Director Kahn Clare bought $9,924 worth of shares (1,860 units at $5.34), increasing direct ownership by 169% to 2,960 units (SEC Form 4)

    4 - Solid Biosciences Inc. (0001707502) (Issuer)

    3/13/25 4:05:03 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Bain Capital Life Sciences Investors, Llc bought $4,030,000 worth of shares (1,000,000 units at $4.03) (SEC Form 4)

    4 - Solid Biosciences Inc. (0001707502) (Issuer)

    2/21/25 5:48:02 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KPRX
    $PROC
    $QNRX
    $SLDB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Development Officer Daniels Eric Joseph covered exercise/tax liability with 238 shares, decreasing direct ownership by 0.90% to 26,137 units (SEC Form 4)

    4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)

    3/6/26 2:03:53 PM ET
    $KPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Strem Brian M. covered exercise/tax liability with 238 shares, decreasing direct ownership by 0.52% to 45,865 units (SEC Form 4)

    4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)

    3/6/26 2:03:29 PM ET
    $KPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    COO & CBO Swartz Robin sold $24,347 worth of shares (6,458 units at $3.77), decreasing direct ownership by 3% to 199,738 units (SEC Form 4)

    4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)

    2/26/26 9:48:09 AM ET
    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KPRX
    $PROC
    $QNRX
    $SLDB
    Financials

    Live finance-specific insights

    View All

    Quoin Pharmaceuticals Announces Second Quarter 2025 Financial Results and Corporate Update

    -  Positive 6 Month Clinical Data Reported for Ongoing Pediatric Netherton Syndrome Study -  FDA Clears Second Pivotal Study of QRX003 for Netherton Syndrome -  Initial Positive Data Announced from Peeling Skin Syndrome Pediatric Study -  Orphan Drug Designation Granted by European Medicines Agency for QRX003 -  Rare Pediatric Disease Designation Awarded by U.S. FDA -  NETHERTON NOW Campaign Expanded with New Patient and Expert Video Releases ASHBURN, Va., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases provided a corporate upda

    8/7/25 8:30:00 AM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2025 Financial Results

    Continued Progress in Ongoing Late-Stage Netherton Syndrome Studies Announced Positive Clinical Data for Adult and Pediatric Netherton Patients Provided Clear Visual Evidence of QRX003 Mechanism of Action Patent Portfolio Expanded to Support Pipeline GrowthLaunch of NETHERTON NOW Advocacy Initiative ASHBURN, Va., May 13, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a late clinical-stage, specialty pharmaceutical company focused on developing and commercializing novel treatments for rare and orphan diseases, today provides a business update and announces financial results for the quarter ended March 31, 2025. Quoin CEO Dr. Michael Myers

    5/13/25 8:00:00 AM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025

    - Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in NHP study - - Preclinical murine data strengthen case for specifically targeting pathologic forms of tau with the clinical-stage anti-tau antibody VY7523 - - Voyager to host live webcast on April 7 recapping key AD/PD™ 2025 data - LEXINGTON, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported new data from its two preclinical programs targeting tau for the treatment of Alzheimer's di

    3/31/25 7:00:47 AM ET
    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KPRX
    $PROC
    $QNRX
    $SLDB
    Leadership Updates

    Live Leadership Updates

    View All

    Quoin Pharmaceuticals Appoints New Chief Financial Officer to Support Commercialization Strategy

    ASHBURN, Va., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a late clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announced the appointment of its new Chief Financial Officer as the Company advances its lead product candidate, QRX003, through pivotal clinical studies and prepares for potential commercialization. Quoin has appointed Sally Lawlor, BCL, FCA, as its new Chief Financial Officer, effective immediately. Ms. Lawlor is an accomplished finance executive with over 20 years of experience in financial leadership roles in public and private companies as well as a Big Four accounting fir

    8/18/25 8:30:00 AM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

    WELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors. Ms. Drapkin will assume the role of Audit Committee Chair, and Mr. Cumbo will assume the role of Compensation Committee Chair. "We are delighted to welcome Kim and Bo to our Board of Directors at Climb Bio," said Aoife Brennan, President and CEO of Climb Bio. "Kim and Bo each bring three decades of leadership experience in the biotechnology and pharmaceutical industry, offering invaluable perspective as we continue to build the company and advance our pipeline. Their insight

    4/1/25 7:00:00 AM ET
    $ABOS
    $CLYM
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Procaps Group Announces Key Shareholder and Board Decisions, Committee Restructuring, and Leadership Updates

    MIAMI and BARRANQUILLA, Colombia, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical services company, today announced significant outcomes from its recent Shareholders Meeting and subsequent Board of Directors meeting. These include changes to the Board composition, restructuring of Board committees, and updates to its executive leadership team. The Shareholders Meeting marked an important milestone with the election of new members to the Board of Directors. The newly elected members bring a diverse range of expertise and strategic insight to guide Procaps' future growth. Newly app

    12/20/24 4:53:03 PM ET
    $PROC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KPRX
    $PROC
    $QNRX
    $SLDB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Procaps Group S.A.

    SC 13D/A - Procaps Group, S.A. (0001863362) (Subject)

    12/3/24 7:20:10 PM ET
    $PROC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Solid Biosciences Inc.

    SC 13D/A - Solid Biosciences Inc. (0001707502) (Subject)

    11/14/24 7:59:25 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Quoin Pharmaceuticals Ltd.

    SC 13G/A - Quoin Pharmaceuticals, Ltd. (0001671502) (Subject)

    11/14/24 7:23:29 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care